{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T04:04:12Z","timestamp":1751342652407,"version":"3.41.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,29]]},"DOI":"10.7759\/cureus.87004","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T05:08:06Z","timestamp":1751260086000},"source":"Crossref","is-referenced-by-count":0,"title":["Anti-MDA5 Antibody-Positive Dermatomyositis-Associated Interstitial Lung Disease With a False-Positive Tuberculosis-Targeted RNA Capture (TB-TRC) Result: A Multimodal Management"],"prefix":"10.7759","author":[{"given":"Miho","family":"Shibata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyoshi","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Himuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takato","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Masutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2024.0072","article-title":"Idiopathic inflammatory myopathies-associated interstitial lung disease in adults","volume":"88","author":"Moda M","year":"2025","unstructured":"Moda M, Yanagihara T, Nakashima R, Sumikawa H, Shimizu S, Arai T, Inoue Y. Idiopathic inflammatory myopathies-associated interstitial lung disease in adults. Tuberc Respir Dis (Seoul). 2025, 88:26-44. 10.4046\/trd.2024.0072","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.52.1116","article-title":"Mycobacterium shinjukuense lung disease that was successfully treated with antituberculous drugs","volume":"52","author":"Watanabe K","year":"2013","unstructured":"Watanabe K, Shinkai M, Yamaguchi N, Shinoda M, Hara Y, Ishigatsubo Y, Kaneko T. Mycobacterium shinjukuense lung disease that was successfully treated with antituberculous drugs. Intern Med. 2013, 52:2653-5. 10.2169\/internalmedicine.52.1116","journal-title":"Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.14932\/jamt.14-103","article-title":"Detection of Mycobacterium tuberculosis (MTB) and Mycobacterium avium complex (MAC) by TRCReady MTB\/MAC autoassay","volume":"64","author":"Onohara K","year":"2015","unstructured":"Onohara K, Yoshida H, Tazawa T, Matsushita A, Kawahara K, Hashimoto S. Detection of Mycobacterium tuberculosis (MTB) and Mycobacterium avium complex (MAC) by TRCReady MTB\/MAC autoassay. Japanese J Med Technol. 2015, 64:483-8. 10.14932\/jamt.14-103","journal-title":"Japanese J Med Technol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01758-09","article-title":"Clinical evaluation of TRCRapid M.TB for detection of Mycobacterium tuberculosis complex in respiratory and nonrespiratory specimens","volume":"48","author":"Tanaka H","year":"2010","unstructured":"Tanaka H, Hirose H, Kato Y, Kida S, Miyajima E. Clinical evaluation of TRCRapid M.TB for detection of Mycobacterium tuberculosis complex in respiratory and nonrespiratory specimens. J Clin Microbiol. 2010, 48:1536-41. 10.1128\/JCM.01758-09","journal-title":"J Clin Microbiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2169\/naika.100.3637","article-title":"Case report: a case of pulmonary infectious disease due to Mycobacterium shinjukuense [Article in Japanese]","volume":"100","author":"Futatsugi K","year":"2011","unstructured":"Futatsugi K, Nishio K, Aida S, et al.. Case report: a case of pulmonary infectious disease due to Mycobacterium shinjukuense [Article in Japanese]. Nihon Naika Gakkai Zasshi. 2011, 100:3637-9. 10.2169\/naika.100.3637","journal-title":"Nihon Naika Gakkai Zasshi"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.42785","article-title":"Prognostic role of interferon-\u03bb3 in anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated interstitial lung disease","volume":"76","author":"Fukada A","year":"2024","unstructured":"Fukada A, Fujisawa T, Hozumi H, et al.. Prognostic role of interferon-\u03bb3 in anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated interstitial lung disease. Arthritis Rheumatol. 2024, 76:796-805. 10.1002\/art.42785","journal-title":"Arthritis Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"121","author":"Hozumi H","year":"2016","unstructured":"Hozumi H, Fujisawa T, Nakashima R, et al.. Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease. Respir Med. 2016, 121:91-9. 10.1016\/j.rmed.2016.10.019","journal-title":"Respir Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key060","article-title":"Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients","volume":"57","author":"Sato S","year":"2018","unstructured":"Sato S, Masui K, Nishina N, et al.. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology (Oxford). 2018, 57:1212-21. 10.1093\/rheumatology\/key060","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono T","year":"2010","unstructured":"Gono T, Kawaguchi Y, Satoh T, et al.. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010, 49:1713-19. 10.1093\/rheumatology\/keq149","journal-title":"Rheumatology (Oxford)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez185","article-title":"Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD","volume":"58","author":"Horiike Y","year":"2019","unstructured":"Horiike Y, Suzuki Y, Fujisawa T, et al.. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD. Rheumatology (Oxford). 2019, 58:2143-52. 10.1093\/rheumatology\/kez185","journal-title":"Rheumatology (Oxford)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010436","article-title":"Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: a case report","volume":"97","author":"Endo Y","year":"2018","unstructured":"Endo Y, Koga T, Suzuki T, et al.. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: a case report. Medicine (Baltimore). 2018, 97:e0436. 10.1097\/MD.0000000000010436","journal-title":"Medicine (Baltimore)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi M","year":"2020","unstructured":"Shirakashi M, Nakashima R, Tsuji H, et al.. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford). 2020, 59:3284-92. 10.1093\/rheumatology\/keaa123","journal-title":"Rheumatology (Oxford)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez357","article-title":"Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy","volume":"59","author":"Abe Y","year":"2020","unstructured":"Abe Y, Kusaoi M, Tada K, Yamaji K, Tamura N. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology (Oxford). 2020, 59:767-71. 10.1093\/rheumatology\/kez357","journal-title":"Rheumatology (Oxford)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2021.101464","article-title":"Early intervention of plasma exchange combined with intensive immunosuppressive treatment for anti-MDA-5 antibody-positive rapidly progressive interstitial pneumonia: two case reports","volume":"33","author":"Ishiwari M","year":"2021","unstructured":"Ishiwari M, Togashi Y, Takoi H, et al.. Early intervention of plasma exchange combined with intensive immunosuppressive treatment for anti-MDA-5 antibody-positive rapidly progressive interstitial pneumonia: two case reports. Respir Med Case Rep. 2021, 33:101464. 10.1016\/j.rmcr.2021.101464","journal-title":"Respir Med Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/11795476211036322","article-title":"Successful treatment of anti-MDA5 antibody-positive dermatomyositis-associated rapidly progressive-interstitial lung disease by plasma exchange: two case reports","volume":"14","author":"Takahashi R","year":"2021","unstructured":"Takahashi R, Yoshida T, Morimoto K, et al.. Successful treatment of anti-MDA5 antibody-positive dermatomyositis-associated rapidly progressive-interstitial lung disease by plasma exchange: two case reports. Clin Med Insights Case Rep. 2021, 14:11795476211036322. 10.1177\/11795476211036322","journal-title":"Clin Med Insights Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/03000605231198742","article-title":"Plasma exchange for anti-MDA5 antibody-positive dermatomyositis-associated rapidly progressive interstitial lung disease: a case report and literature review","volume":"51","author":"Lu C","year":"2023","unstructured":"Lu C, Xu C, Zhu X, Han Y. Plasma exchange for anti-MDA5 antibody-positive dermatomyositis-associated rapidly progressive interstitial lung disease: a case report and literature review. J Int Med Res. 2023, 51:3000605231198742. 10.1177\/03000605231198742","journal-title":"J Int Med Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.626953","article-title":"Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study","volume":"8","author":"Liang J","year":"2021","unstructured":"Liang J, Cao H, Yang Y, et al.. Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study. Front Med (Lausanne). 2021, 8:626953. 10.3389\/fmed.2021.626953","journal-title":"Front Med (Lausanne)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2020.101272","article-title":"Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies","volume":"31","author":"Yanagihara T","year":"2020","unstructured":"Yanagihara T, Suzuki K, Egashira A, et al.. Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies. Respir Med Case Rep. 2020, 31:101272. 10.1016\/j.rmcr.2020.101272","journal-title":"Respir Med Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson SR","year":"2024","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, et al.. 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 2024, 76:1182-200. 10.1002\/art.42861","journal-title":"Arthritis Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01488-2024","article-title":"Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study","volume":"65","author":"Wu W","year":"2025","unstructured":"Wu W, Guo B, Sun W, et al.. Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study. Eur Respir J. 2025, 65:2401488. 10.1183\/13993003.01488-2024","journal-title":"Eur Respir J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00458-2025","article-title":"Tofacitinib in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a new standard of care emerges","volume":"65","author":"Yanagihara T","year":"2025","unstructured":"Yanagihara T, Mirza RD, Kolb MR. Tofacitinib in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a new standard of care emerges. Eur Respir J. 2025, 65:2500458. 10.1183\/13993003.00458-2025","journal-title":"Eur Respir J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji H","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, et al.. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020, 72:488-98. 10.1002\/art.41105","journal-title":"Arthritis Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.883699","article-title":"Mortality risk stratification using cluster analysis in patients with myositis-associated interstitial lung disease receiving initial triple-combination therapy","volume":"9","author":"Gono T","year":"2022","unstructured":"Gono T, Masui K, Sato S, Kuwana M. Mortality risk stratification using cluster analysis in patients with myositis-associated interstitial lung disease receiving initial triple-combination therapy. Front Med (Lausanne). 2022, 9:883699. 10.3389\/fmed.2022.883699","journal-title":"Front Med (Lausanne)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/381014-anti-mda5-antibody-positive-dermatomyositis-associated-interstitial-lung-disease-with-a-false-positive-tuberculosis-targeted-rna-capture-tb-trc-result-a-multimodal-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T05:08:07Z","timestamp":1751260087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/381014-anti-mda5-antibody-positive-dermatomyositis-associated-interstitial-lung-disease-with-a-false-positive-tuberculosis-targeted-rna-capture-tb-trc-result-a-multimodal-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,29]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.87004","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,29]]}}}